Аннотация:The gastrointestinal (GI) graft-versus host disease (GVHD) remains to be challenging and life-threatening complication of hematopoietic stem cell transplantation (HSCT) in children. Steroid based treatment of this condition remains a universal standard first-line therapy. Despite authorization of new agents for second-line therapy, steroid refractory GI GVHD awaits safer and more effective therapeutic approach.